Clinical trials data
Symbol Coding in cancer trials: 58 registered studies
Every registered cancer study on ClinicalTrials.gov that names Symbol Coding in an outcome measure: how often it is a primary outcome, the tests named with it, how large the studies are and when they measure it.
- Registered cancer studies name it in an outcome measure
- 58
- Name it in a primary outcome, 47%
- 27 of 58
Tests named in the same studies
- 1
Verbal Learning32 studies, 15 as a primary outcome
- 2
Digit Span Test27 studies, 14 as a primary outcome
- 3
Trail Making Test27 studies, 13 as a primary outcome
- 4
Verbal Fluency26 studies, 13 as a primary outcome
- 5
Stroop Color-Word Test11 studies, 6 as a primary outcome
- 6
Category Fluency6 studies, 2 as a primary outcome
- 7
Paced Visual Serial Addition Test5 studies, 2 as a primary outcome
- 8
Short Story Recall5 studies, 2 as a primary outcome
- 9
Continuous Performance Test4 studies, 3 as a primary outcome
- 10
Complex Figure Copy and Recall3 studies, 2 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
Studies by start year
A test as a primary outcomeOnly in secondary or other outcomes
Show as a table
| Start year | Studies | A test as a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 1 | 0 |
| 2009 | 1 | 1 |
| 2010 | 1 | 1 |
| 2011 | 1 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 5 | 2 |
| 2015 | 1 | 0 |
| 2016 | 1 | 0 |
| 2017 | 4 | 1 |
| 2018 | 2 | 2 |
| 2019 | 2 | 0 |
| 2020 | 2 | 1 |
| 2021 | 6 | 3 |
| 2022 | 6 | 5 |
| 2023 | 6 | 1 |
| 2024 | 9 | 3 |
| 2025 | 2 | 2 |
| 2026 | 7 | 5 |
Phases and study sizes
By phase
- Early phase 11 studies, 1 as a primary outcome
- Phase 13 studies, 0 as a primary outcome
- Phase 23 studies, 1 as a primary outcome
- Phase 36 studies, 2 as a primary outcome
- Phase 41 studies, 1 as a primary outcome
- Not applicable27 studies, 10 as a primary outcome
- Observational17 studies, 12 as a primary outcome
Participants per study
- Not applicable84 median, 41 to 145
- Observational60 median, 40 to 100
Show as a table
| Phase | Studies with a size | Median | Middle half |
|---|---|---|---|
| Not applicable | 27 | 84 | 41 to 145 |
| Observational | 17 | 60 | 40 to 100 |
When cancer trials measure it
Latest time point of each outcome
- Within a day5 outcomes, 2 as a primary outcome
- Up to 4 weeks8 outcomes, 3 as a primary outcome
- 1 to 3 months14 outcomes, 7 as a primary outcome
- 3 to 6 months12 outcomes, 5 as a primary outcome
- 6 to 12 months9 outcomes, 4 as a primary outcome
- 1 to 2 years3 outcomes, 2 as a primary outcome
- Over 2 years5 outcomes, 2 as a primary outcome
- No duration given2 outcomes, 2 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
56 of the 58 outcome measures give a duration. A single visit counts as within a day.
Status, results, interventions and countries
Status
- Recruiting12 studies, 8 as a primary outcome
- Not yet recruiting5 studies, 3 as a primary outcome
- Active, not recruiting7 studies, 3 as a primary outcome
- Completed20 studies, 6 as a primary outcome
- Stopped early6 studies, 2 as a primary outcome
- Status unknown8 studies, 5 as a primary outcome
What they test
- Behavioral22 studies, 10 as a primary outcome
- Drug14 studies, 5 as a primary outcome
- Device6 studies, 2 as a primary outcome
- Dietary supplement2 studies, 2 as a primary outcome
- Procedure1 studies, 0 as a primary outcome
- Diagnostic test2 studies, 1 as a primary outcome
- Radiation3 studies, 0 as a primary outcome
- Other15 studies, 7 as a primary outcome
- None given7 studies, 5 as a primary outcome
Intervention types as registered. A study can list several; observational studies often list none.
Where their sites are
- United States24 studies, 8 as a primary outcome
- Italy8 studies, 5 as a primary outcome
- Canada7 studies, 2 as a primary outcome
- France4 studies, 0 as a primary outcome
- China3 studies, 2 as a primary outcome
- Denmark3 studies, 1 as a primary outcome
- Spain3 studies, 2 as a primary outcome
- Belgium2 studies, 0 as a primary outcome
- Germany2 studies, 0 as a primary outcome
- Netherlands2 studies, 0 as a primary outcome
- United Kingdom2 studies, 1 as a primary outcome
- Australia1 studies, 1 as a primary outcome
22 countries in all. A study with sites in several counts in each; 4 list no site.
Reported results
Completed studies with results posted on ClinicalTrials.gov, a results paper the registry links to the study, or both.
Completed cancer studies that name Symbol Coding: 10 of 20, 50%
Every completed study with a cognitive outcome: 3,626 of 7,953, 46%
| Results | Completed cancer studies that name Symbol Coding | Every completed study |
|---|---|---|
| Results on ClinicalTrials.gov and a paper | 3, 15% | 776, 10% |
| Results on ClinicalTrials.gov only | 3, 15% | 1,139, 14% |
| A results paper only | 4, 20% | 1,711, 22% |
| Neither | 10, 50% | 4,327, 54% |
The 58 studies
58 studies match. 27 name Symbol Coding in a primary outcome. Median size 82 participants. Median time to the primary outcome: 6 months.
Loading 58 studies; the filters turn on when they arrive.
2026 is partly planned starts. Not shown: 1 that started before 2000.
Show as a table
| Start year | Studies | As a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 1 | 0 |
| 2009 | 1 | 1 |
| 2010 | 1 | 1 |
| 2011 | 1 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 5 | 2 |
| 2015 | 1 | 0 |
| 2016 | 1 | 0 |
| 2017 | 4 | 1 |
| 2018 | 2 | 2 |
| 2019 | 2 | 0 |
| 2020 | 2 | 1 |
| 2021 | 6 | 3 |
| 2022 | 6 | 5 |
| 2023 | 6 | 1 |
| 2024 | 9 | 3 |
| 2025 | 2 | 2 |
| 2026 | 7 | 5 |
Library tests named most
Largest condition groups
Phases
Participants
Lead sponsor: industry 6, NIH 1, other 51. Interventional 41, observational 17.
As a primary outcomeSecondary or other outcomeSymbol Coding
The studies, newest registration first
Each number opens the study's record on ClinicalTrials.gov.
| Study | Start | Phase | Conditions | Participants | Lead sponsor | Status | Library tests named, with the latest time point |
|---|---|---|---|---|---|---|---|
| NCT07836478 | Start2026 | PhaseObservational | ConditionsCancer | Participants60 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07710131 | Start2026 | PhaseNot applicable | ConditionsCancer | Participants36 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07652476 | Start2026 | PhaseObservational | ConditionsCancer | Participants100 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07633626 | Start2026 | PhaseObservational | ConditionsDepression and bipolar disorder, Cancer | Participants24 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07479927 | Start2025 | PhaseNot applicable | ConditionsCancer | Participants40 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07463781 | Start2026 | PhaseObservational | ConditionsCancer | Participants100 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07341217 | Start2026 | PhaseNot applicable | ConditionsCancer, Aging, frailty and exercise | Participants86 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06937554 | Start2025 | PhaseObservational | ConditionsCancer | Participants30 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06727370 | Start2024 | PhaseObservational | ConditionsCancer, Lung disease | Participants200 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06610617 | Start2024 | PhaseNot applicable | ConditionsCancer | Participants48 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT06606535 | Start2024 | PhaseObservational | ConditionsCancer | Participants60 | Lead sponsorOther | StatusStatus unknown | Library tests named
|
| NCT06553235 | Start2024 | PhaseNot applicable | ConditionsCancer, Sleep and sleep disorders | Participants84 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06468176 | Start2024 | PhaseNot applicable | ConditionsCancer | Participants187 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06330298 | Start2021 | PhaseNot applicable | ConditionsStroke, Multiple sclerosis, Cancer | Participants84 | Lead sponsorOther | StatusStatus unknown | Library tests named
|
| NCT06219902 | Start2024 | PhasePhase 1 | ConditionsCancer | Participants64 | Lead sponsorIndustry | StatusCompleted | Library tests named
|
| NCT06136923 | Start2023 | PhaseNot applicable | ConditionsMultiple sclerosis, Cancer | Participants194 | Lead sponsorIndustry | StatusCompleted | Library tests named
|
| NCT06112639 | Start2024 | PhaseNot applicable | ConditionsDementia and Alzheimer's, Mild cognitive impairment, Multiple sclerosis, Cancer | Participants192 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06103318 | Start2024 | PhaseNot applicable | ConditionsCancer | Participants176 | Lead sponsorOther | StatusStatus unknown | Library tests named
|
| NCT06055231 | Start2026 | PhasePhase 1 | ConditionsCancer, Substance use and addiction | Participants40 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT05907265 | Start2023 | PhaseNot applicable | ConditionsCancer | Participants60 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT05896189 | Start2024 | PhaseNot applicable | ConditionsCancer | Participants386 | Lead sponsorOther | StatusActive, not recruiting | Library tests named
|
| NCT05716542 | Start2023 | PhaseNot applicable | ConditionsCancer | Participants41 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT05708716 | Start2022 | PhaseNot applicable | ConditionsCancer | Participants80 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT05704855 | Start2023 | PhaseNot applicable | ConditionsCancer | Participants21 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT05671094 | Start2023 | PhaseNot applicable | ConditionsCancer | Participants21 | Lead sponsorOther | StatusCompleted | Library tests named
|
Questions, answered from the data
How many cancer trials use Symbol Coding?
58 registered cancer studies on ClinicalTrials.gov name it in an outcome measure, 27 of them in a primary outcome: 8% of the condition's 760 studies with a cognitive outcome, against 9% of all of them. It is the 6th most named test in cancer trials.
Which tests do cancer trials use with Symbol Coding?
Verbal Learning (32 studies), the Digit Span Test (27 studies) and the Trail Making Test (27 studies).
When do cancer trials measure Symbol Coding?
Half of the primary outcomes that name Symbol Coding are measured within 6 months of the start, and the middle half from 12 weeks to 12 months. 25 primary outcomes give a duration.
How many completed cancer trials that use Symbol Coding have reported results?
10 of the 20 completed studies that name it, 50%, have reported results: 6 posted them on ClinicalTrials.gov, 7 have a results paper linked to the registry record, and 3 did both. The other 10 show neither. Of all completed studies with a cognitive outcome, 46% have reported results.
How the studies are counted
For each test family, the census runs ClinicalTrials.gov's own outcome search for the family's names and reads every study first posted by the day the family was counted. These studies were read on 10 November 2026. A study counts once on a page, however many tests it names. Counts for a test cover every version of the task under any of its names, so a page can count studies that used a commercial version.
The census adds two things to each record and changes nothing in it: which outcome list names the test (primary, then secondary, then other), and the condition groups, matched on the study's condition names and MeSH terms. A study can fall in several groups; one whose only condition is cognitive impairment or decline falls in “Cognitive impairment and decline”. Studies that name only instruments outside the library count in every total and share but are not listed.
A second read on 10 November 2026 added each study's overall status, whether results are posted, its intervention types, the countries of its sites and the time frame of the outcome that names each test. A time frame counts by the latest time point it names: “Baseline, 12 and 24 weeks” is 24 weeks, a single visit is within a day, and one that names no duration, such as “end of treatment”, is left out of the timings.
A third read on 10 November 2026 added the papers the registry links to each study: those its sponsor lists as reporting results, and those PubMed links to it through the study's NCT number. A study has a results paper when one of them came out in or after the month of its primary completion and PubMed does not class it as a protocol, review or comment. A paper that never gives the NCT number is not linked, so some studies counted as reporting neither did publish.
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine, which does not endorse these pages. Every study line is in the data release 2.1.0, and the explorer's own file is clinical-trials-studies.json.
The census counts Symbol Key Game and Symbol Coding as one test family, so this page counts their studies together.
Run Symbol Coding in your trial
Choose tests with a record in registered trials, and run them in a browser at every site, on the same version each visit.